Company Profile
Comera Stock Price, News & Catalysts
- Ticker:
- CMRA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.00 USD
Close
Last updated: July 31, 2026
—
Market cap
Why the stock is moving
Current closing-price context is not available for CMRA.
Company overview
Business overview
Comera was a biotechnology company focused on enabling subcutaneous delivery of biologics through its SQore platform. Its thesis was that better delivery could improve usability and differentiation for injectable therapies.
Geographic Base and Sector Classification
Comera was headquartered in the United States and listed on NASDAQ. It sat in drug-delivery biotechnology.
Business Model Characteristics
The business depended on platform validation, partnering, and capital support to advance its delivery technology. Investors generally watched formulation progress and strategic interest in the platform.
Position Within the Biotechnology Landscape
Comera occupied a drug-delivery niche within biotech. It was more of a platform-enablement story than a classic therapeutic developer.
Future catalysts
- Comera’s catalysts are formulation and subcutaneous-delivery platform updates, plus any strategic step that clarifies its future. The company still needs a cleaner commercial path.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Comera (CMRA)?
Comera (CMRA) most recently closed at 0.00 USD.
What does Comera do?
Comera was a biotechnology company focused on enabling subcutaneous delivery of biologics through its SQore platform. Its thesis was that better delivery could improve usability and differentiation for injectable therapies.
On which exchange is CMRA stock listed?
Comera (CMRA) is associated with NASDAQ, United States, Biopharma.
What is Comera?
Comera’s catalysts are formulation and subcutaneous-delivery platform updates, plus any strategic step that clarifies its future.
Which conditions is Comera targeting with Comera?
Comera’s catalysts are formulation and subcutaneous-delivery platform updates, plus any strategic step that clarifies its future.
How does Comera describe recent progress with Comera?
Comera’s catalysts are formulation and subcutaneous-delivery platform updates, plus any strategic step that clarifies its future.
What is SQore?
Comera was a biotechnology company focused on enabling subcutaneous delivery of biologics through its SQore platform.
What should investors watch for with SQore?
Comera’s catalysts are formulation and subcutaneous-delivery platform updates, plus any strategic step that clarifies its future. The company still needs a cleaner commercial path.